• The transaction, subject to the relevant regulatory approvals and approval by the General Shareholders’ Meeting, will reduce the leverage ratio (Net Financial Debt/Adjusted EBITDA) from 3.8x to 1.1x and lower annual financial expenses by around €13 million.

Atrys Health has signed a share purchase agreement to transfer 100% of Aspy Global Services S.A.U. (ASPY) to Grupo Echevarne, S.L. for €145 million. The agreement also provides for contingent consideration of up to €5 million if the buyer transfers the asset to a third party within one year after closing for an amount higher than the agreed price.

Completion of the transaction is subject to authorisation from the relevant regulatory authorities and approval by Atrys’ General Shareholders’ Meeting, which will be called in the coming days. Closing is expected in the first quarter of 2026.

The divestment of the prevention business will allow Atrys to concentrate resources on its core precision medical diagnosis and treatment businesses, strengthen its financial position, and accelerate organic growth by focusing on business areas where it holds leadership positions and greater return potential.

The proceeds obtained will be used to reduce the Group’s financial debt, targeting a Net Financial Debt/Adjusted EBITDA ratio of around 1.1x (from 3.8x) and annual savings in financial expenses of around €13 million.

Excluding the prevention area (ASPY) from the Atrys Group perimeter, pro forma LTM Revenue (from October 2024 to September 2025) will amount to €142.5 million and the Group’s Adjusted LTM EBITDA to €28.0 million. Pro forma LTM organic revenue growth will increase from the current +8.2% to +13.4%.

Marian Isach, Chief Executive Officer of Atrys, stated: “This transaction strengthens our balance sheet and enables us to focus on the business areas where we have a clear competitive edge and strong growth traction. With lower financing costs and a leaner structure, we will accelerate investment and innovation while reinforcing our international expansion.”

“ASPY has been key to the Group’s development and we will support an orderly transition. This divestment opens a new stage for Atrys, more focused and with a better growth profile,” added Isach.